Objective A systematic review and a meta-analysis were conducted, to investigate the possible association of methylene tetrahydrofolate reductase (MTHFR) gene polymorphisms with adverse effects related to methotrexate (MTX).
Introduction
Methotrexate (MTX) is a widely used drug in the treatment of a variety of diseases such as cancer, acute lymphoblastic leukemia or lymphoma, hematopoietic cell transplantation, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other diseases [1, 2] . As a structural analogue of folic acid, MTX reversibly inhibits dihydrofolate reductase, an enzyme that participates in the tetrahydrofolate synthesis [3] [4] [5] . MTX is also known to inhibit other enzymes in the folic acid cycle, such as thymidylate synthase and methylene tetrahydrofolate reductase (MTHFR) [6, 7] .
As an inhibitor of DNA and protein synthesis, MTX interferes with and inhibits the growth of normal cells and tissues besides the target abnormal cells. It can, therefore, cause a significant number of side effects that may lead to therapy discontinuation. The most common side effects include oral mucositis, nausea, diarrhoea, and alopecia. Furthermore, it may also cause serious toxicities in liver, bone marrow, pulmonary, and the central nervous system [8, 9] . A special kind of toxicity of MTX in patients treated with hematopoietic cell transplantation is acute graft-versus-host disease (GVHD).
MTHFR catalyses the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate in folic acid cycle, and thus, it plays an essential role in nucleotide biosynthesis. In contrast, 5-methyltetrahydrofolate acts as a methyl donor for the remethylation of homocysteine to methionine. There are two common single-nucleotide polymorphisms (SNPs) of MTHFR: C677T and A1298C. The C677T polymorphism changes alanine to valine at the 222 position of the amino acid sequence. The enzyme activity of the TT homozygote is decreased compared with that of the CC homozygote [10, 11] . The A1298C polymorphism is responsible for the substitution of glutamate by alanine at the 429 position of the protein [12, 13] . This polymorphism has been associated with a reduced MTHFR activity in vitro. The reduced enzyme activity leads to high blood homocysteine levels and this disorder is connected to coronary and peripheral artery diseases [14] .
Several research groups have investigated the relevance between MTHFR SNPs and MTX toxicity with conflicting results. Moreover, many individual studies have inadequate power to reveal mild gene effects because of their small sample sizes. Therefore, we conducted a meta-analysis along with many subgroup analyses to summarize the results of separate studies concerning this scientific topic and to explore the potential impact of between-studies heterogeneity on the summary estimates.
Methods

Retrieval of published studies
A systematic, computerized literature search (using PubMed, Scopus, and Google Scholar) for papers published before December 2008 was conducted by two different reviewers. In addition, the two reviewers independently examined the retrieved articles to extract the information needed using a data collection form. The following keywords were utilized: 'Methotrexate', combined with 'MTHFR' or 'Methylene Tetrahydrofolate Reductase' and 'polymorphism' or 'variant'. After an initial screening of titles and abstracts, only relevant articles remained. The qualifying full-text publications and their reference lists were carefully examined to ascertain their relevance to the topic of interest. Furthermore, to eliminate bias resulting from the 'grey literature', studies published in conference proceedings or as short abstracts were also considered. Manuscripts in languages other than English were also considered for review, to avoid the local literature bias. However, only articles published in English were finally retrieved and found to be relevant to the topic of interest.
Inclusion and exclusion criteria
Population-based studies were included in the metaanalysis if (a) they examined the association of MTHFR polymorphisms with MTX toxicity and (b) they provided adequate information (i.e., the genotype or allele counts) for estimating a measure of association [odds Ratio (OR)]. To limit selection bias, language or quality restrictions were avoided [15, 16] . Furthermore, to eliminate bias resulting from the 'grey literature' [17] , studies published in conference proceedings or as short abstracts were also considered. Fig. 1 demonstrates the paper elimination process of the meta-analysis.
Data extraction
The following data were recorded from each study: (a) first author's name, journal, year of publication, ethnicity of participants; (b) number of eligible genotyped participants; (c) the polymorphism under investigation and the disease form; (d) the type of toxicities of MTX and the folate supplementation of patients; (e) the distribution of genotypes and alleles in all the participants.
Statistical analysis
The OR was used to compare the distribution of alleles and genotypes between participants with and without MTX toxicity. Initially, we used a recently proposed multivariate random-effects method of meta-analysis for comparing the effect of other genotypes (TT and CT for C677T and CC and CA for A1298C) against the wild-type genotype CC and AA, respectively, for C677T and A1298C [18] . We also used a recently published methodology for meta-analysis of gene-disease association studies that is based on random-effects logistic regression [19] . Potentially relevant studies identified and screened (n=92)
Studies included in meta-analysis (n=42)
Both methods avoid multiple comparisons and test the genetic model of inheritance directly, whereas the logistic regression method can operate even in the presence of zero cell counts. Their disadvantage is that they require the full genotype distribution (i.e., the TT, CT, and CC counts) from a given study, which may not be available in all cases. For these reasons, we also used the traditional univariate approach based on computing the ORs for three different genetic contrasts (T vs. C allele, TT vs. CT + CC genotypes, and TT + CT vs. CC genotypes for C677T; C vs. A allele, CC vs. AC + AA genotypes, CC + AC vs. AA genotypes for A1298C). The betweenstudies heterogeneity was evaluated using the Cochran's Q statistic [20] and the inconsistency index I 2 [21] . The combined ORs and their 95% confidence intervals (CIs) were estimated applying the random-effects methodology [22] , which is appropriate in case of significant heterogeneity.
In secondary analyses, the summary ORs were stratified by the racial descent of the participants and the Hardy-Weinberg equilibrium (HWE) status of the individuals without MTX toxicity. Deviations from the HWE were calculated by the w 2 method. Besides the analysis of the overall toxicity, we performed subgroup meta-analyses for six types of toxicities and three different forms of diseases. The analysis for the overall toxicity (which was defined as the appearance of any type of adverse effect during MTX therapy, mild or severe, hematological or nonhematological) comprised of two categories including (a) studies with at least one type of MTX toxicity and (b) studies with patients who presented at least two different MTX adverse effects. A separate subanalysis according to the folic acid supplementation of patients was performed in order to investigate the role and a probable interaction of the folate supplement with MTX toxicity. In accordance to this, the studies were divided into three categories: (a) those in which none of the patients was supplied with folic acid, (b) those in which some of the patients were supplied with folic acid, and (c) those in which all the patients were treated with folic acid.
The presence of publication-related or other small-studyrelated bias was assessed using the rank correlation method of Begg and Mazumdar [23] , the Egger et al.'s regression method [24] and its random-effects analogue [25] . Influential studies were detected by checking the effect of removing an individual study on the overall significance of the estimate or on the heterogeneity statistic. Cumulative meta-analysis [26, 27] was applied to identify any trend of the effect estimate with accruing evidence [28] . For the detection of the time-trend, we used the standard cumulative meta-analysis approach, which consists of inspecting the plot visually and a recently proposed regression-based method [29] .
For all analyses, the statistical package STATA 10 (Stata Corporation, College Station, Texas, USA) was used.
Results with a P value of less than 0.05 were considered to be statistically significant.
Results
In total, 44 studies concerning the association of MTHFR gene polymorphisms with MTX toxicity were populated in our meta-analysis (Table 1 ). In particular, 26 studies addressed the C677T polymorphism, three studies examined the A1298C polymorphism, and the remaining 15 studies provided data for both polymorphisms. One of the studies [53] included information about three independent populations, and thus, it was counted as three studies in the meta-analysis.
MTHFR C677T polymorphism (rs1801133)
Overall toxicity: more than two adverse effects
In total, eighteen studies [31] [32] [33] [34] [35] 37, [42] [43] [44] 47, 49, 51, 53, 56, 57, 60, 61, 69] examined the association of C677T polymorphism with the appearance of at least two adverse effects of MTX. Among them, six studies were conducted in Caucasian populations, seven in Asian populations, and five studies in other ethnicities. Seven studies were found to be in HWE [47, 49, 51, 56, 57, 60, 61] . The logistic regression model was applied in eight studies [47, 49, 51, 53, 56, 57, 60, 61] and provided a statistically significant effect in the TT versus CC contrast (OR: 1.672, 95% CI: 1.009, 2.769). The multivariate methodology (included eight studies [47, 49, 51, 53, 56, 57, 60, 61] ) also yielded a very similar estimate in TT versus CC genotype (OR: 1.670, 95% CI: 1.000, 2.770). The l value was 0.39, which indicates a possible codominant model of inheritance.
The conventional meta-analysis was conducted in 18 studies [31] [32] [33] [34] [35] 37, [42] [43] [44] 47, 49, 51, 53, 56, 57, 60, 61, 69] . The per-allele OR of the T variant was 1.217 (95% CI: 0.889, 1.665). A much higher, but marginally not significant effect was detected in the TT versus CT + CC contrast (OR: 1.566, 95% CI: 0.949, 2.582). However, the analysis revealed a significant result in the TT versus CT + CC comparison in studies concerning Asian populations (OR: 1.655, 95% CI: 1.029, 2.660) and in studies in HWE (OR: 1.604, 95% CI: 1.063, 2.419). Heterogeneity was not observed in most calculations, and there was no evidence for publication bias. Sensitivity analysis revealed a single influential study [49] . After removing this study from the analysis, the OR value decreased essentially (T vs. C OR: 1.043, 95% CI: 0.856, 1.269). The cumulative analysis showed a decrease in the effect over years (data not shown).
Overall toxicity: more than one adverse effect Forty-one articles investigated the association of C677T polymorphism and the appearance of at least one MTX adverse event. Fifteen studies enrolled Caucasian populations, 12 studies enrolled Asian populations, and 14 were applied in other ethnicities. We found 18 studies The first 15 patients were treated with oral MTX 1.25 mg every 12 h for 21 days. After a 2-week rest, this regimen was repeated. As no objective response was noted in these patients, another group of 28 patients were enrolled, to be treated with a 21day MTX (1.25 mg every 12 h).
Overall None
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. The association of the polymorphism with digestive system toxicity, neurotoxicity, GVHD, and mucositis was also studied. The subanalysis concerning gastrointestinal adverse effects found no association with the C677T polymorphism. As far as the nervous system adverse effects are concerned, logistic regression and multivariate models could not be used because of a lack of the necessary data. The univariate random-effects models detected a significant effect on neurotoxicity in the TT versus CC + CT contrast (OR: 3.398, 95% CI: 1.808, 6.389).
Our analysis concerning GVHD presents a protective role of the C677T polymorphism in the incidence of this type of toxicity. Rheumatoid arthritis, hematological disorders, and hematopoietic cell transplantation subgroups concern patients who presented any form of toxicity (mild or severe; hematological, or nonhematological) during MTX treatment for the respective disease. Patients who came up with only one side effect by the drug use were included in the analysis.
As far as rheumatoid arthritis is concerned, we came up with a total of 15 studies. The OR of the TT versus CC comparison provided by the logistic regression was 1.991 (95% CI: 0.982, 4.036). The multivariate method provided similar results (included six studies, [49, 53, 57, 61] There was no publication bias, but betweenstudies heterogeneity was shown in some calculations.
Role of folic acid supplementation
The possible genetic effect in the appearance of MTX pharmacotoxicity due to the folate supplementation of patients was aimed to be elucidated. The multivariate methodology recruited 11 studies in the category of no folic acid supplementation, three studies in the category of partial folic acid supplementation, and six articles in the category of full folic acid supplementation. It was shown that the C677T polymorphism is associated with higher levels of toxicity in patients who were treated with MTX and folic acid as well. The OR derived under the random-effects logistic regression for the TT versus CC contrast was equal to 2.871 (95% CI: 1.107, 7.450) and that of CT versus CC was equal to 2.736 (95% CI: 1.347, 5.559) for patients taking folic acid. The same results occurred when the multivariate model was applied. In contrast, no relation between MTX adverse events and the C677T polymorphism was found concerning the other categories (no folic acid supplementation and partial folic acid supplementation).
The classical meta-analysis methodology found no association between the MTHFR polymorphism and MTX toxicity in all cases of folate treatment. Twenty-three studies for the no folate supplementation group, ten studies for the partial supplementation subgroup, and eight articles for full folate supplementation of patients were included. No association between the mutant allele and the MTX toxicity for patients treated with folic acid supplementation (OR: 1.511, 95% CI: 0.897, 2.546) was indicated. The results of the C677T polymorphism analysis are presented in Tables 2 and 3 .
MTHFR A1298C polymorphism (rs1801131)
Overall toxicity: more than two adverse effects Initially, we came up with a total of 12 studies examining the relation of the polymorphism with the presence of at least two adverse effects of MTX treatment. Four papers [60] [61] [62] 71] were consistent with the HWE in participants without MTX toxicity. The logistic regres-sion and multivariate methods failed to yield significant results. The univariate meta-analysis provided similar insignificant results. Heterogeneity was present in some contrasts. The cumulative analysis did not provide any trend in the effect estimates over time in any of the contrasts examined (data not shown). 
Discussion
The present meta-analysis aims to clarify the association of MTHFR C677T and A1298C gene polymorphisms with MTX-related toxicity. An association between the C677T MTHFR variant and toxicity as an outcome of MTX treatment is indicated. In detail, logistic regression and multivariate models revealed a significant effect of the TT genotype for patients who presented at least two adverse events. The effect of the polymorphism on hepatotoxicity has been clearer. In contrast, a protective role of C677T polymorphism on the occurrence of GVHD was determined. Our analysis has managed to demonstrate a significant association between 677C > T polymorphism and a lower risk of GVHD in patients undergoing hematopoietic stem cell transplantation. Our findings are consistent with the idea that the lower MTHFR activity due to the 677C > T polymorphism offers patients treated with MTX greater immunosuppres-sion. However, there are studies that failed to show any relation between MTHFR polymorphisms in patients receiving MTX and the incidence of GVHD. Eventually, evidence was provided by logistic regression and multivariate models that the 677T homozygous supplemented with folate have a significantly elevated risk to present MTX toxicity. Finally, the observations of our analysis concerning the C677T polymorphism and toxicity in rheumatoid arthritis patients are consistent with those provided by a previous meta-analysis, [72] concluding in a mild association using random-effects models.
The logistic regression analysis of the A1298C polymorphism highlighted a significant relation between C allele carriers and MTX toxicity in patients who presented at least one adverse effect. Furthermore, evidence for a significantly elevated risk of toxicity is provided for C allele carriers who were not supplemented with folic acid during MTX treatment. Our analysis concluded to a protective role of the CC homozygous rheumatoid arthritis patients against the appearance of MTX adverse events, although this is conflicting with a previous meta-analysis [72] .
MTX is a drug with a wide usage in a variety of disorders and in many regimens. Tissues undergoing rapid cell division and growth are the most susceptible to its effects. This mechanism also explains the possible severe side effects of MTX. MTX toxicity includes a significant number of different forms for almost all human organs. Therefore, it is probably a complicated biological issue where many factors are involved. Many researchers have tried to exemplify the metabolic pathways and the genetic impact of MTX toxicity [73] [74] [75] . MTX side effects can only partly be explained by folate antagonism and may also depend on its action on other related metabolic pathways. Recent data on the issue include the homocysteine-methionine-polyamine pathway and purine metabolism [75] . Many studies have investigated the role of the adenosine pathway in MTX toxicities [76, 77] . Further investigation is needed to clarify all the aspects of the patient.
In contrast, many investigators have tried to relate the higher risk for MTX adverse effects with gene polymorphisms. There are a large number of case-control studies aimed to investigate the two most common polymorphisms of the MTHFR gene. The C677T and A1298C SNPs of MTHFR have been identified as a risk factor for elevated MTX toxicity by many primary studies, whereas others concluded that there was no association. Other genetic variants are also analyzed. A recent study yielded evidence for the association with ABCB1 3435C > T (ATP-binding cassette) and TLR4 + 896A > G (toll-like receptor 4) [78] . SNPs in SLCO1B1 (solute carrier organic anion transporter family) and ADORA2a (adenosine receptor 2a) were significantly associated with gastrointestinal toxicity [79, 80] . Thus, MTX toxicity may be influenced by additional polymorphisms and these should be examined in further studies [81, 82] .
The MTHFR gene and its polymorphisms hold an essential position in scientific research concerning the folic acid cycle. The two most common polymorphisms lead to decreased enzyme activity followed by hyperhomocysteinemia. Previous studies have tried to investigate the role of MTHFR SNPs with different diseases and disorders. The C677T polymorphism is considered to be a risk factor for thrombofilia and pregnancy complications [83, 84] . Moreover, there is serious evidence that polymorphisms in the MTHFR gene predispose one to neural tube defects and schizophrenia [85, 86] . The C677T polymorphism also seems to be associated with a reduced risk of colorectal cancer, but this may not hold true for all populations [87] . Finally, in the last decade, there was evidence that elevated plasma homocysteine is associated with an increased risk of atherosclerosis and cardiovascular disease. Several studies have tried to prove an effect of the C677T polymorphism on the risk of cardiovascular events, but the results remain conflicting [88] .
Our analysis aims to exemplify the role of folic acid supplementation in the appearance of MTX toxicity in patients carrying a polymorphism in MTHFR gene. We have shown that the C677T polymorphism is associated with a higher risk of toxicity in patients supplemented with folate.
This verification seems paradoxical as one would expect that folate supplementation plays a protective role. A possible explanation could be the fact that patients who received a higher folate dose were probably in the most severe condition, and thus, are more likely to present MTX side effects. This particular phenomenon is common in observational studies, where the term 'confounding by indication' has been suggested [89] . Clearly, a meta-analysis of published results can only provide hints in this direction, and additional and carefully designed studies are necessary to elucidate this very important issue. In contrast, the A1298C MTHFR The subanalysis concerning studies with patients who presented more than two types of side effects. b The subanalysis concerning studies with patients who presented more than one type of side effect. c The subanalysis concerning studies with rheumatoid arthritis patients. d The subanalysis based on folate supplementation status of the patients.
polymorphism was associated with increased MTX toxicity in studies that did not include folate supplementation. However, many investigators suggest that folate supplementation reduces the risk of MTX adverse effects and it should be prescribed in every case [90] .
In conclusion, our analysis suggests that MTHFR SNPs are associated with overall MTX toxicity. Our results also included a significant association with specific types of adverse effects and a positive role of polymorphisms in some cases. Future individual studies and meta-analyses are necessary to confirm our conclusions and set the foundations of individualized treatment. Finally, further investigation is needed to detect the exact biological pathways and mechanisms explaining MTX toxicity and genetic associations.
